{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T12:57:44Z","timestamp":1762865864400},"reference-count":29,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1016\/j.ygyno.2011.08.018","type":"journal-article","created":{"date-parts":[[2011,10,10]],"date-time":"2011-10-10T17:53:15Z","timestamp":1318269195000},"page":"479-485","source":"Crossref","is-referenced-by-count":22,"title":["Phase III trial of induction gemcitabine or paclitaxel plus carboplatin followed by paclitaxel consolidation in ovarian cancer"],"prefix":"10.1016","volume":"123","author":[{"given":"Alan N.","family":"Gordon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Teneriello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mike F.","family":"Janicek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Hines","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter C.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Dwight","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Vaccarello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Howard D.","family":"Homesley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"McMeekin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiana L.","family":"Burkholder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luping","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauro","family":"Orlando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Coleman K.","family":"Obasaju","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John F.","family":"Gill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Datchen F.","family":"Tai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2011.08.018_bb0005","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3322\/caac.20073","article-title":"Cancer statistics 2010","volume":"60","author":"Jemal","year":"2010","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ygyno.2011.08.018_bb0010","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1093\/jnci\/dji289","article-title":"Annual report to the nation on the status of cancer, 1975\u20132002, featuring population-based trends in cancer treatment","volume":"97","author":"Edwards","year":"2005","journal-title":"J Natl Cancer Inst"},{"issue":"suppl 10","key":"10.1016\/j.ygyno.2011.08.018_bb0015","doi-asserted-by":"crossref","first-page":"S129","DOI":"10.1200\/JCO.2003.04.003","article-title":"Progress in the management of gynecologic cancer: consensus summary statement","volume":"21","author":"Cannistra","year":"2003","journal-title":"J Clin Oncol"},{"issue":"2 suppl 6","key":"10.1016\/j.ygyno.2011.08.018_bb0020","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1053\/j.seminoncol.2006.03.011","article-title":"Systemic therapy for ovarian cancer: current status and new treatments","volume":"33","author":"Ozols","year":"2006","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ygyno.2011.08.018_bb0025","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(02)09738-6","article-title":"Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial","volume":"360","author":"The International Collaborative Ovarian Neoplasm (ICON) Group","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2011.08.018_bb0030","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","article-title":"Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study","volume":"21","author":"Ozols","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2011.08.018_bb0035","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/jnci\/djg036","article-title":"A randomized clinical trial of cisplatin\/paclitaxel versus carboplatin\/paclitaxel as first-line treatment of ovarian cancer","volume":"95","author":"du Bois","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2011.08.018_bb0040","doi-asserted-by":"crossref","first-page":"4162","DOI":"10.1200\/JCO.2009.27.4696","article-title":"Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer","volume":"28","author":"du Bois","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2011.08.018_bb0045","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1023\/A:1011605008922","article-title":"Second-line carboplatin and gemcitabine in platinum sensitive ovarian cancer\u2014a dose-finding study by the Arbeitsgemeinschaft Gyn\u00e4kologische Onkologie (AGO) Ovarian Cancer Study Group","volume":"12","author":"du Bois","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ygyno.2011.08.018_bb0050","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1006\/gyno.2002.6855","article-title":"Phase II trial of gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed ovarian cancer patients","volume":"88","author":"Nagourney","year":"2003","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.08.018_bb0055","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ygyno.2004.10.011","article-title":"A phase II study of gemcitabine plus carboplatin in platinum-sensitive, recurrent ovarian carcinoma","volume":"96","author":"Kose","year":"2005","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.08.018_bb0060","doi-asserted-by":"crossref","first-page":"4699","DOI":"10.1200\/JCO.2006.06.0913","article-title":"Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG","volume":"24","author":"Pfisterer","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2011.08.018_bb0065","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0090-8258(03)00413-X","article-title":"Gemcitabine combined with cisplatin as first-line treatment in patients with epithelial ovarian cancer: a phase II study","volume":"91","author":"Belpomme","year":"2003","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.08.018_bb0070","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1097\/00001813-200209000-00009","article-title":"Phase II study of gemcitabine and cisplatin in chemonaive patients with advanced epithelial ovarian cancer","volume":"13","author":"Nogu\u00e9","year":"2002","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.ygyno.2011.08.018_bb0075","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1046\/j.1525-1438.2003.13039.x","article-title":"Gemcitabine combined with cisplatin as first-line treatment in patients 60years or older with epithelial ovarian cancer: a phase II study","volume":"13","author":"Bauknecht","year":"2003","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ygyno.2011.08.018_bb0080","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0169-5002(03)00140-5","article-title":"Randomized, multicenter, phase II study of gemcitabine plus cisplatin versus gemcitabine plus carboplatin in patients with advanced non-small cell lung cancer","volume":"41","author":"Mazzanti","year":"2003","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ygyno.2011.08.018_bb0085","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1200\/JCO.2003.07.013","article-title":"Phase III randomized trial of 12 versus 3months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response and platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial","volume":"21","author":"Markman","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2011.08.018_bb0090","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3816\/COC.2009.n.011","article-title":"Phase III trial of induction gemcitabine or paclitaxel plus carboplatin followed by elective paclitaxel consolidation in ovarian cancer: interim analysis of induction chemotherapy","volume":"2","author":"Gordon","year":"2009","journal-title":"Clin Ovar Cancer"},{"issue":"suppl 15s","key":"10.1016\/j.ygyno.2011.08.018_bb0095","article-title":"Phase III trial of induction gemcitabine (G) or paclitaxel (T) plus carboplatin (C) followed by elective T consolidation in advanced ovarian cancer (OC): interim analysis of induction chemotherapy","volume":"26","author":"Gordon","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2011.08.018_bb0100","unstructured":"National Cancer Institute Common Toxicity Criteria Version 2.0 (http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/ctcv20_4-30-992.pdf)."},{"key":"10.1016\/j.ygyno.2011.08.018_bb0105","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"issue":"suppl 10","key":"10.1016\/j.ygyno.2011.08.018_bb0110","doi-asserted-by":"crossref","first-page":"S187","DOI":"10.1200\/JCO.2003.01.223","article-title":"Use of CA-125 to assess response to new agents in ovarian cancer trials","volume":"21","author":"Rustin","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2011.08.018_bb0115","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/sim.4780010204","article-title":"Tables of the number of patients required in clinical trials using the logrank test","volume":"1","author":"Freedman","year":"1982","journal-title":"Stat Med"},{"key":"10.1016\/j.ygyno.2011.08.018_bb0120","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2307\/2281868","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.ygyno.2011.08.018_bb0125","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ygyno.2007.08.092","article-title":"Clinical trial endpoints in ovarian cancer: report of an FDA\/ASCO\/AACR\/Public Workshop","volume":"107","author":"Bast","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.08.018_bb0130","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ygyno.2003.09.021","article-title":"Second-line chemotherapy with gemcitabine and carboplatin in paclitaxel-pretreated, platinum-sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group Study","volume":"92","author":"Papadimitriou","year":"2004","journal-title":"Gynecol Oncol"},{"issue":"suppl 18S","key":"10.1016\/j.ygyno.2011.08.018_bb0135","volume":"24","author":"Bookman","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2011.08.018_bb0140","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ygyno.2004.10.001","article-title":"Experience with single-agent paclitaxel consolidation following primary chemotherapy with carboplatin, paclitaxel, and gemcitabine in advanced OC","volume":"96","author":"Micha","year":"2005","journal-title":"Gynecol Oncol"},{"issue":"suppl 18S","key":"10.1016\/j.ygyno.2011.08.018_bb0145","article-title":"Carboplatin (C) plus paclitaxel (P) versus carboplatin plus pegylated liposomal doxorubicin (PLD) in patients with advanced ovarian cancer (AOC): final analysis of the MITO-2 randomized multicenter trial","volume":"28","author":"Pignata","year":"2010","journal-title":"J Clin Oncol"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825811007037?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825811007037?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T16:25:22Z","timestamp":1543508722000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825811007037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["S0090825811007037"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2011.08.018","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2011,12]]}}}